Table 3. Enrichment of rare NRAP variants in patients with dilated cardiomyopathy (DCM).

	Control group	Non-DCM cardiac group	OR (95% CI), P-value	DCM group	OR (95% CI), p-value
Individuals (n)	25912	5150		577
Dominant hypothesis
Only one PTV variant	75 (0.29%)	24 (0.47%)	1.61 (1.02–2.56), p = 0.04	11 (1.91%)	6.71 (3.5–12.7), p<0.0001
Only one missense variant	698 (2.45%)	132 (2.56%)	1.05 (0.86–1.26), p = 0.65	10 (1.74%)	0.70 (0.4–1.3), p = 0.27
Recessive hypothesis
Two missense variants	27 (0.10%)	1 (0.02%)	0.18 (0.02–1.35), p = 0.10	0 (0.0%)	0.81 (0.05–13.4), p = 0.89
One PTV + one missense	0	0	NA	6 (1.04%)	590 (33–10494), p<0.0001
Two PTV variants	0	0	NA	5 (0.87%)	407 (22–7575), p<0.0001
PTV + missense or 2 PTVs	0	0	NA	11 (1.91%)	1052(62–17876), p<0.0001

Control group patients underwent genetic testing due to non-cardiac reasons and non-DCM group patients due to cardiological reasons excluding patients with DCM or suspected DCM. DCM group includes patients tested with a DCM Panel or other panels because of confirmed or suspected DCM. Abbreviations: pts, patients; OR, odds ratio; 95% CI, 95% confidence interval, DCM, dilated cardiomyopathy, PTV, Protein-truncating variant (means here nonsense, frameshift variant, consensus splice site, start lost). Only variants with 100 or fewer heterozygous individuals in a gnomAD reference population cohort were included in calculations.